Table 1.

Clinical features of 179 mCRC patients who received GOLFIG chemo-immunotherapy between June 2002 and June 2018.

Sex	n.	Treatment line	n.	Primary sidedness	n.	K/N-ras	n.	irAEs	n.
Male	106	First line	62	Left	112	WT	41	No	136
Female	73	> 2 lines	117	Right	67	Mut	33	Yes	43

Sixty two of them had been enrolled in the GOLFIG-2 phase III trial and received frontline treatment. One hundred seventeen patients received salvage treatment after two/three treatment lines. Forty-nine of them had been enrolled in the GOLFIG-1 phase II trial, and 68 received the GOLFIG chemo-immunotherapy as real-world treatment. mCRC, metastatic colorectal cancer; GOLFIG, gemcitabine, oxaliplatin, LF, and fluorouracil poly-chemotherapy with granulocyte-macrophage colony stimulating factor and interleukin-2); irAEs, immune-related adverse events.